Arbutus Biopharma announced the appointment of Melissa Rewolinski, PhD, to its board of directors, effective July 12, 2023. Dr. Rewolinski currently serves as principal of MVR Consulting, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ABUS:
- Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
- Arbutus Biopharma appoints Karen Sims as chief medical officer
- Arbutus Appoints Two New Executives
- Arbutus Biopharma management to meet virtually with JMP Securities
- Arbutus doses first patient in additional treatment arm of Phase 2a trial